98%
921
2 minutes
20
The Amazon region possesses vast natural and anthropogenic ecosystems within a hydroclimatic environment conducive to the proliferation of arboviruses associated with infectious diseases in the human population, notably dengue fever, which poses a recurrent and significant public health challenge. : We wished to update the dengue mapping for the state of Pará (eastern Amazon) using municipality-level secondary data between 2010 and 2024, including epidemiological information. Furthermore, the seasonal effects of soil and atmospheric meteorological variables (ERA5 reanalysis) on the annual municipal incidence of dengue were statistically analyzed through correlation and cluster-based regression methods. : Dengue mapping identified key areas over the central, southwest, and southeast parts of Pará, with eleven municipalities exhibiting extreme dengue counts exceeding 300 cases per 100,000 inhabitants. The epidemiological profile in these cities with worsening transmission showed a higher incidence in adults aged 20-39 years old (39%) and a predominance among women (54%). The majority of dengue cases occur during the rainy season (January to May), accounting for 69% of annual cases, when the climate conditions maximize vector proliferation. The statistical analyses highlighted the significant and spatially heterogeneous influence of regional climate variables on the dengue transmission cycle. : This study advances our understanding of climatic drivers of dengue in the Amazon and provides relevant evidence to support region-specific surveillance and control strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197224 | PMC |
http://dx.doi.org/10.3390/reports8020061 | DOI Listing |
Epidemiol Serv Saude
September 2025
Universidade de Brasília, Faculdade de Medicina, Brasília, DF, Brazil.
Objective: To analyze the temporal trend of dengue incidence and lethality rates and the proportions of its serotypes, in the different macro-regions of Brazil, between 2001 and 2022. In particular, the immediate and gradual effects of these indicators were verified in the periods before and after the publication of the National Guidelines for the Prevention and Control of Dengue Epidemics.
Methods: This was an interrupted time series analysis.
New Microbes New Infect
October 2025
Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Background: Dengue is a mosquito-borne viral infection with growing global impact, including international travellers travelling to and from endemic regions. This systematic literature review aimed to assess the clinical and economic burden of dengue in travellers from non-endemic countries.
Methods: This systematic review was conducted following the PRISMA guidelines to assess the incidence, prevalence, mortality, healthcare resource use, and costs of dengue fever in travellers between non-endemic and endemic regions.
Appl Biosaf
August 2025
Mahidol-Oxford Tropical Research Medicine Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Introduction: Dengue virus (DENV) poses a significant global health threat, particularly in tropical and subtropical regions, where it is primarily transmitted by spp. mosquitoes. Its biosafety and biosecurity management present unique challenges due to both its vector-borne nature and rare instances of nonvector transmission.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Beijing Institute of Tropical Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory for Research on Prevention and Treatment of Tropical Diseases, Beijing, China.
Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world's population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease.
View Article and Find Full Text PDFMed
September 2025
Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore; Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore; Department of Clinical Translational Research, Singapore General Hospital, Singapo
Background: All three dengue vaccines that have completed phase 3 clinical trials have shown greater efficacy in dengue-seropositive compared to dengue-seronegative individuals. This includes the live-attenuated tetravalent dengue vaccine TAK-003, where immunogenicity in baseline seronegative individuals remains lower after two doses, despite seroconversion after the first dose, compared to baseline seropositive individuals after one dose.
Methods: A whole-genome microarray was used to analyze the host response to TAK-003.